Komiyama Shinichi, Katabuchi Hidetaka, Mikami Mikio, Nagase Satoru, Okamoto Aikou, Ito Kiyoshi, Morishige Kenichiro, Suzuki Nao, Kaneuchi Masanori, Yaegashi Nobuo, Udagawa Yasuhiro, Yoshikawa Hiroyuki
Department of Gynecology, Toho University Ohashi Medical Center, 2-17-6 Ohashi, Meguro-ku, Tokyo, 153-8515, Japan.
Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Int J Clin Oncol. 2016 Jun;21(3):435-46. doi: 10.1007/s10147-016-0985-x. Epub 2016 May 3.
The fourth edition of the Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer was published in 2015. The guidelines contain seven chapters and six flow charts. The major changes in this new edition are as follows-(1) the format has been changed from reviews to clinical questions (CQ), and the guidelines for optimal clinical practice in Japan are now shown as 41 CQs and answers; (2) the 'flow charts' have been improved and placed near the beginning of the guidelines; (3) the 'basic points', including tumor staging, histological classification, surgical procedures, chemotherapy, and palliative care, are described before the chapter; (4) the FIGO surgical staging of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer was revised in 2014 and the guideline has been revised accordingly to take the updated version of this classification into account; (5) the procedures for examination and management of hereditary breast and ovarian cancer are described; (6) information on molecular targeting therapy has been added; (7) guidelines for the treatment of recurrent cancer based on tumor markers alone are described, as well as guidelines for providing hormone replacement therapy after treatment.
日本妇科肿瘤学会关于卵巢癌(包括原发性腹膜癌和输卵管癌)治疗的指南第四版于2015年发布。该指南包含七个章节和六个流程图。新版的主要变化如下:(1)格式从综述改为临床问题(CQ),日本最佳临床实践指南现呈现为41个临床问题及答案;(2)“流程图”得到改进并置于指南开头附近;(3)在章节之前描述了包括肿瘤分期、组织学分类、手术程序、化疗和姑息治疗在内的“基本要点”;(4)2014年对卵巢癌、输卵管癌和原发性腹膜癌的FIGO手术分期进行了修订,指南也相应修订以考虑该分类的更新版本;(5)描述了遗传性乳腺癌和卵巢癌的检查及管理程序;(6)增加了分子靶向治疗的信息;(7)描述了仅基于肿瘤标志物的复发性癌症治疗指南以及治疗后提供激素替代疗法的指南。